Logo image of JUNS

JUPITER NEUROSCIENCES INC (JUNS) Stock Fundamental Analysis

NASDAQ:JUNS - Nasdaq - US48208B2034 - Common Stock - Currency: USD

1.65  +0.46 (+38.66%)

After market: 1.53 -0.12 (-7.27%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to JUNS. JUNS was compared to 195 industry peers in the Pharmaceuticals industry. JUNS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. JUNS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JUNS has reported negative net income.
In the past year JUNS has reported a negative cash flow from operations.
In the past 5 years JUNS always reported negative net income.
In the past 5 years JUNS always reported negative operating cash flow.
JUNS Yearly Net Income VS EBIT VS OCF VS FCFJUNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

JUNS has a Return On Assets of -77.13%. This is in the lower half of the industry: JUNS underperforms 70.26% of its industry peers.
JUNS's Return On Equity of -114.66% is on the low side compared to the rest of the industry. JUNS is outperformed by 61.03% of its industry peers.
Industry RankSector Rank
ROA -77.13%
ROE -114.66%
ROIC N/A
ROA(3y)-1983.37%
ROA(5y)-11078.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JUNS Yearly ROA, ROE, ROICJUNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

JUNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JUNS Yearly Profit, Operating, Gross MarginsJUNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for JUNS has been increased compared to 1 year ago.
The number of shares outstanding for JUNS has been increased compared to 5 years ago.
Compared to 1 year ago, JUNS has an improved debt to assets ratio.
JUNS Yearly Shares OutstandingJUNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
JUNS Yearly Total Debt VS Total AssetsJUNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

JUNS has an Altman-Z score of 8.72. This indicates that JUNS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of JUNS (8.72) is better than 85.64% of its industry peers.
JUNS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
JUNS has a Debt to Equity ratio (0.04) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 8.72
ROIC/WACCN/A
WACCN/A
JUNS Yearly LT Debt VS Equity VS FCFJUNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

A Current Ratio of 2.31 indicates that JUNS has no problem at all paying its short term obligations.
With a Current ratio value of 2.31, JUNS perfoms like the industry average, outperforming 41.54% of the companies in the same industry.
JUNS has a Quick Ratio of 2.31. This indicates that JUNS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.31, JUNS is in line with its industry, outperforming 48.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.31
JUNS Yearly Current Assets VS Current LiabilitesJUNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for JUNS have decreased by 0.00% in the last year.
Looking at the last year, JUNS shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-383%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -14.19% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66%
EPS Next 2Y-10.63%
EPS Next 3Y47.73%
EPS Next 5Y-14.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JUNS Yearly Revenue VS EstimatesJUNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 2M 4M 6M 8M 10M
JUNS Yearly EPS VS EstimatesJUNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 0.1 -0.1 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JUNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year JUNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JUNS Price Earnings VS Forward Price EarningsJUNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JUNS Per share dataJUNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as JUNS's earnings are expected to grow with 47.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.63%
EPS Next 3Y47.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JUNS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (7/3/2025, 5:00:02 PM)

After market: 1.53 -0.12 (-7.27%)

1.65

+0.46 (+38.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)N/A N/A
Inst Owners1.17%
Inst Owner Change7346.32%
Ins Owners45.71%
Ins Owner Change0.21%
Market Cap54.62M
Analysts82.86
Price Target30.6 (1754.55%)
Short Float %1.88%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)16.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.09
P/tB 13.09
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.13%
ROE -114.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1983.37%
ROA(5y)-11078.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.31
Altman-Z 8.72
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-383%
EPS Next Y66%
EPS Next 2Y-10.63%
EPS Next 3Y47.73%
EPS Next 5Y-14.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.47%
OCF growth 3YN/A
OCF growth 5YN/A